Several tyrosine kinase inhibitors (TKIs) have been approved in Europe by the European Medicines Agency (EMA) for NSCLC: the EGFR inhibitors (EGFRi) afatinib (AFT), erlotinib (ERL), gefitinib (GEF), and osimertinib (OSI); the ALK inhibitors (ALKi) alectinib (ALEC), brigatinib (BRG), ceritinib (CER), crizotinib (CRIZ), and lorlatinib (LORL); the vascular endothelial growth factor (VEGF) inhibitor (VEGFi) nintedanib (NTB). This evidence concerns the gene EGFR and non-small cell lung carcinoma.